Paclitaxel prodrugs: Toward smarter delivery of anticancer agents

Journal of Medicinal Chemistry

Volumn 49, Issue 25, 2006, Pages 7253-7269

  Skwarczynski, Mariusz ^a   Hayashi, Yoshio ^a   Kiso, Yoshiaki ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2' [3 (N,N DIETHYLAMINO)PROPIONYL]PACLITAXEL; ANTIBODY CONJUGATE; CARBOXYL GROUP; CARBOXYMETHYLCYCLODEXTRAN; CREMOPHOR; DENDRIMER; DEXTRAN DERIVATIVE; HYALURONIC ACID; MACROGOL; METHYL GREEN; N (2 HYDROXYPROPYL)METHACRYLAMIDE; ORGANOPHOSPHATE; PACLITAXEL; POLYGLUTAMIC ACID; PRODRUG;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; CONJUGATE; CYCLIZATION; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HYDROPHILICITY; HYPOXIA; LIPOPHILICITY; MACROMOLECULE; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PACLITAXEL; PRODRUGS;

EID: 33845508580     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0602155     Document Type: Review

References (178)

1. Wani, M. C.; Taylor, H.L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant antitumor agents. VI. Isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93, 2325-2327.
2. Mekhail, T. M.; Markman, M. Paclitaxel in cancer therapy. Expert Opin. Pharmacather. 2002, 3, 755-766.
3. Ferlini, C.; Ojima, I.; Distefano, M.; Gallo, D.; Riva, A.; Morazzoni, P.; Bombardelli, E.; Mancuso, S.; Scambia, G. Second generation taxanes: from the natural framework to the challenge of drug resistance. Curr. Med. Chem.: Anti-Cancer Agents 2003, 3, 133-138.
4. Nabholtz, J.-M; Vannetzel, J. M.; Llory, J.-F.; Bouffette, P. Advances in the use of taxanes in the adjuvant therapy of breast cancer, Clin. Breast Cancer 2003, 4, 187-192.
5. Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of microtubule assembly in vitro by Taxol. Nature 1979, 277, 665-667.
6. Dancey, J.; Sausville, E. A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discovery 2003, 2, 296-313.
7. McDaid, H. M.; Lopez-Barcons, L.; Grossman, A.; Lia, M.; Keller. S.; Perez-Soler, R.; Horwitz, S. B. Enhancement of the therapeutic efficacy of Taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res. 2005, 65, 2854-2860.
8. Garofalo, A.; Naumova, E.; Manenti, L.; Ghilardi, C.; Ghisleni, G.; Caniatti, M.; Colombo, T.; Cherrington, J. M.; Scanziani, E.; Nicoletti, M. I.; Giavazzi, R. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin. Cancer Res. 2003, 9, 3476-3485.
9. Taxman, D. J.; MacKeigan, J. P.; Clements, C.; Bergstralh, D. T.; Ting, J. P.-Y. Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor. Cancer Res. 2003, 63, 5095-5104.
10. Ciardiello, F.; Caputo, R.; Damiano, V.; Caputo, R.; Troiani, T.; Vitagliano, D.; Carlomagno, F.; Veneziani, B. M.; Fontanini, G.; Bianco, A. R.; Tortora, G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Rex. 2003, 9, 1546-1556.
11. Kim, S. J.; Uehara, H.; Karashima, T.; Shepherd, D. L.; Killion, J. J.; Fidler, I. J. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin. Cancer Res. 2003, 9, 1200-1210.
12. Li, G. Faibushevich, A.; Turunen, B. J.; Yoon, S. O.; Georg, G.; Michaelis, M. L.; Dobrowsky, R. T. Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases β-amyloid toxicity in cortical neurons. J. Neurochem. 2003, 84, 347-362.
13. Yusuf, R. Z.; Duan, Z.; Lamendola, D. E.; Pensen, R. T.; Seiden, M. V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr. Cancer Drug Targets 2003, 3, 1-19.
14. Singla, A. K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations. Int. J. Pharm. 2002, 255, 179-192.
15. ten Tije, A. J.; Verweij, J.; Loos, W. J.; Sparreboom, A. Pharmacological cological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 2003, 42, 665-685.
16. Ng, S. S. W.; Fig, W. D.; Sparreboom, A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res. 2004, 64, 821-824.
17. Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 2004, 47, 2393-2404.
18. Testa, B. Prodrug research: futile or fertile? Biochem. Pharmacol. 2004, 68, 2097-2106.
19. Stella, V. J. Prodrug as therapeutics. Expert Opin. Ther. Pat. 2004, 14, 277-280.
20. Ferguson M. J.; Ahmed, F. Y.; Cassidy, J. The role of prodrug therapy in the treatment of cancer. Drug Resist. Updates 2001, 4, 225-232.
21. Ter Haar, E. Taxanes and other microtubule stabilizing agents. Expert Opin. Ther. Pat. 1998, 8, 571-586.
22. Lin, S.; Ojima, I. Recent strategies in the development of taxane anticancer drugs. Expert Opin. Ther. Pat. 2000, 10, 869-889.
23. Dubois, J.; Guenard, D.; Gueritte, F. Recent developments in antitumour taxoids. Expert Opin. Ther. Pat. 2003, 13, 1809-1823.
24. Fang, W. S.; Liang, X. T. Recent progress in structure activity relationship and mechanistic studies of taxol analogues. Mini-Rev. Med. Chem. 2005, 5, 1-12.
25. Greenwald, R. B.; Choe, Y. H.; McGuire, J.; Conover, C. D. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Delivery Rev. 2003, 55, 217-250.
26. Maison, W.; Frangioni, J. V. Improved chemical strategies for the targeted therapy of cancer. Angew. Chem., Int. Ed. 2003, 42, 4726-4728.
27. Jaracz, S.; Chen, J.; Kuznetsova, L. V.; Ojima, I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 2005, 13, 5043-5054.
28. Wu, X.; Ojima, I. Tumor specific novel taxoid-monoclonal antibody conjugates. Curr. Med. Chem. 2004, 11, 429-438.
29. Vyas, D. M. Paclitaxel (Taxol) Formulation and Prodrugs. In The Chemistry and Pharmacology of Taxol and Its Derivatives; Ed.; Farina, V., Ed.; Elsevier: Amsterdam, The Netherlands, 1995; pp 103-130.
30. Zhu, Q.; Guo, Z.; Huang, N.; Wang, M.; Chu, F. Comparative molecular field analysis of a series of paclitaxel analogs. J. Med. Chem. 1997, 40, 4319-4328.
31. Kingston, D. G. I. Recent advances in the chemistry of Taxol. J. Nat. Prod. 2000, 63, 726-734.
32. Vyas, D. M.; Wong, H.; Crosswell, A. R.; Casazza, A. M.; Knipe, J. O.; Mamber, S. W.; Doyle, T. W. Synthesis and antitumor evaluation of water soluble taxol phosphates. Bioorg. Med. Chem. Lett. 1993. 3, 1357-1360.
33. Hayashi, Y.; Skwarczynsi, M.; Hamada, Y.; Sohma, Y.; Kimura, T.; Kiso, Y. A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no by product: Design and synthesis of isotaxel. J. Med. Chem. 2003, 46, 3782-3784.
34. Deutsch, H. M.; Glinski, J. A.; Hernandez, M.; Haugwitz, R. D.; Narayanan, V. L.; Suffness, M.; Zalkow, L. H. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity. J. Med. Chem. 1989, 32, 788-792.
35. Zhao, Z.; Kingston, D. G. I.; Crosswell, A. R. Modified Taxols. 6. Preparation of water-soluble prodrugs of Taxol. J. Nat. Prod. 1991, 54, 1607-1611.
36. Mathew, A. E.; Mejillano, M. R.; Nath, J. P.; Himes, R. H.; Stella, V. J. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J. Med. Chem. 1992, 35, 145-151.
37. Nicolaou, K. C.; Riemer, C.; Kerr, M. A.; Rideout, D.; Wrasidlo, W. Design, synthesis and biological activity of protaxols. Nature 1993, 364, 464-466.
38. Tietze, L. F.; Feuerstein, T. Enzyme and proton-activated prodrugs for a selective cancer therapy. Curr. Pharm. Des. 2003, 9, 2155-2175.
39. Nicolaou, K. C.; Guy, R. K.; Pitsinos, E. N.; Wrasidlo, W. A water-soluble prodrug of taxol with self-assembling properties. Angew. Chem., Int. Ed. Engl. 1994, 33, 1583-1587.
40. Ueda, Y.; Wong, H.; Matiskella, J. D.; Mikkilineni, A. B.; Farina, V.; Fairchild, C.; Rose, W. C.; Mamber, S. W.; Long, B. H.; Kerns, E. H.; Casazza, A. M.; Vyas, D. M. Synthesis and antitumor evaluation of 2′- oxycarbonylpaclitaxels (paclitaxel-2′-carbonates). Bioorg. Med. Chem. Lett. 1994. 4, 1861-1864.
41. Matsumoto, H.; Sohma, Y.; Kimura, T.; Hayashi, Y.; Kiso, Y. Controlled drug release: new water-soluble prodrugs of an HIV protease inhibitor. Bioorg. Med. Chem. Lett. 2001, 11, 605-609 and references cited therein.
42. Ueda, Y.; Mikkilineni, A. B.; Knipe, J. O.; Rose, W. C.; Casazza, A. M.; Vyas, D. M. Novel water soluble phosphate prodrugs of taxol possessing in vivo antitumor activity. Bioorg. Med. Chem. Lett. 1993, 3, 1761-1766.
43. Ueda, Y.; Matiskella, J. D.; Mikkilineni, A. B.; Farina, V.; Knipe, J. O.; Rose, W. C.; Casazza, A. M.; Vyas, D. M. Novel, water-soluble phosphate derivatives of 2′-ethoxycarbonylpaclitaxel as potential prodrugs of paclitaxel: synthesis and antitumor evaluation. Bioorg. Med. Chem. Lett. 1995, 5, 247-252.
44. Golik, J.; Wong, H. S. L.; Chen, S. H.; Doyle, T. W.; Wright, J. J.; Knipe, J.; Rose, W. C.; Casazza, A. M.; Vyas, D. M. Synthesis and antitumor evaluation of paclitaxel phosphonooxymethyl ethers: a novel class of water soluble paclitaxel prodrugs. Bioorg, Med. Chem. Lett. 1996, 6, 1837-1842.
45. Senter, P. D.; Marquardt, H.; Thomas, B. A.; Hammock, B. D.; Frank, L. S.; Svensson, H. P. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. Cancer Res. 1996, 56, 1471-1474.
46. Rooseboom, M.; Commandeur, J. N. M.; Vermeulen, N. P. E. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 2004, 56, 53-102.
47. Moosavi-Movahedi, A. A.; Hakimelahi, S.; Chamani, J.; Khodarahmi, G. A.; Hassanzadeh, F.; Luo, F. T.; Ly, T. W.; Shia, K.-S.; Yen, C. F.; Jain, M. L.; Kulatheeswaran, R.; Xue, C.; Pasdar, M.; Hakimelahi, G. H. Design, synthesis, and anticancer activity of phosphonic acid diphosphate derivative of adenine-containing butenolide and its water-soluble derivatives of paclitaxel with high antitumor activity. Bioorg. Med. Chem. 2003, 11, 4303-4313.
48. Paradis, R.; Page, M. New active paclitaxel amino acids derivatives with improved water solubility. Anticancer Res. 1998, 18, 2711-2716.
49. Wrasidlo, W.; Gaedicke, G.; Guy, R. K.; Renaud, J.; Pitsinos, E.; Nicolaou, K. C.; Reisfeld, R. A.; Lode, H. N. A novel 2′-(N- methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models. Bioconjugate Chem. 2002, 13, 1093-1099.
50. Qasem, J. G.; Bummer, P. M.; Digenis, G. A. Kinetics of paclitaxel 2′-N-methylpyridinium mesylate decomposition. AAPS PharmSciTech 2003, 4, 164-171.
51. Khmelnitsky, Y. L.; Budde, C.; Arnold, M. J.; Usyatinsky, A.; Clark. D. S.; Dordick, J. S. Synthesis of water-soluble paclitaxel derivatives by enzymatic acylation. J. Am. Chem. Soc. 1997, 119, 11554-11555.
52. Mandai, T.; Okumoto, H.; Oshitari, T.; Nakanishi, K.; Mikuni, K.; Hara, K. J.; Hara, K. Z.; Iwatani, W.; Amano, T.; Nakamura, K.; Tsuchiya, Y. Synthesis and biological evaluation of water soluble taxoids bearing sugar moieties. Heterocycles 2001, 54, 561-566.
53. Damen, E. W. P.; Wiegerinck, P. H. G.; Braamer, L.; Sperling, D.; de Vos, D.; Scheeren, H. W. Bioorg. Med. Chem. 2000, 8, 427-432.
54. Kirschberg, T. A.; VanDeusen, C. L.; Rothbard, J. B.; Yang, M.; Wender. P. A. Arginine-based molecular transporters: the synthesis and chemical evaluation of releasable Taxol-transporter conjugates. Org. Lett. 2003, 5, 3459-3462.
55. Rothbard, J. B.; Kreider, E.; VanDeusen, C. L.; Wright, L.; Wylie, B. L.; Wender, P. A. Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J. Med. Chem. 2002, 45, 3612-3618.
56. Futaki, S.; Goto, S.; Sugiura, Y. Membrane permeability commonly shared among arginine-rich peptides. J. Mol. Recognit. 2003, 16, 260-264.
57. Rothbard, J. B.; Jessop, T. C.; Wender, P. A. Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv. Drug Delivery-Rev. 2005, 57, 495-504.
58. Battaglia, A.; Guerrini, A.; Baldelli, E.; Fontana, G.; Varchi, G.; Samori, C.; Bombardelli, E. Synthesis of 7- and 10-spermine conjugates of paclitaxel and 10-deacetyl-paclitaxel as potential prodrugs. Tetrahedron Lett. 2006, 47, 2667-2670.
59. Wang, S.; Zhelev, N. Z.; Duff, S.; Fischer, P. M. Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin. Bioorg. Med. Chem. Lett. 2006, 16, 2628-2631.
60. Seligson, A. L.; Terry, R. C.; Bressi, J. C.; Douglass, J. G., III; Sovak. M. A new prodrug of paclitaxel: synthesis of protaxel. Anti-Cancer Drugs 2001, 12, 305-313.
61. Niethammer, A.; Gaedicke, G.; Lode, H. N.; Wrasidlo, W. Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility. Bioconjugate Chem. 2001, 12, 414-420.
62. Wrasidlo, W.; Niethammer, A.; Deger, S.; Sehouli, J.; Kulozik, A.; Geilen, W.; Henze, G.; Gaedicke, G.; Lode, H. N. Pilot study of hydrolytically activated paclitaxel prodrug therapy in patients with progressive malignancies. Curr. Ther. Res. 2002, 63, 247-262.
63. Schroeder, U.; Bernt, K. M.; Lange, B.; Wenkel, J.; Jikai, J.; Shabat, D.; Amir, R.; Huebener, N.; Niethammer, A. G.; Hagemeier, C.; Wiebusch, L.; Gaedicke, G.; Wrasidlo, W.; Reisfeld, R. A.; Lode, H. N. Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia. Blood 2003, 102, 246-253.
64. Brass, E. P. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol. Rev. 2002, 54, 589-598.
65. Luer, M. S. Fosphentoin. Neurol. Res. 1998, 20, 178-182.
66. Sohma, Y.; Hayashi, Y.; Skwarczynski, M.; Hamada, Y.; Sasaki, M.; Kimura, T.; Kiso, Y. Q-N intramolecular acyl migration reaction in the development of prodrugs and the synthesis of difficult sequence-containing bioactive peptides. Biopolymers 2004, 76, 344-356.
67. Skwarczynski, M.; Sohma, Y.; Kimura, M.; Hayashi, Y.; Kimura, T.; Kiso, Y. O-N intramolecular acyl migration strategy in water-soluble prodrugs of taxoids. Bioorg. Med. Chem. Lett. 2003, 13, 4441-4444.
68. Skwarczynski, M.; Sohma, Y.; Noguchi, M.; Kimura, M.; Hayashi, Y.; Hamada, Y.; Kimura, T.; Kiso, Y. No auxiliary, no byproduct strategy for water-soluble prodrugs of taxoids: scope and limitation of O-N intramolecular acyl and acyloxy migration reactions. J. Med. Chem. 2005, 48, 2655-2666.
69. Huang, P. S.; Oliff, A. Drug-targeting strategies in cancer therapy. Curr. Opin. Genet. Dev. 2001, 11, 104-110.
70. Kakugawa, Y.; Wada, T.; Yamaguchi, K.; Yamanami, H.; Ouchi, K.; Sato, I.; Miyagi, T. Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 10718-10723.
71. Takahashi, T.; Tsukamoto, H.; Yamada, H. Design and synthesis of a water-soluble Taxol analogue: Taxol-sialyl conjugate. Bioorg. Med. Chem. Lett. 1998, 8, 113-116.
72. De Groot, F. M. H.; Darnen, E. W. P.; Scheeren, H. W. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. Curr. Med. Chem. 2001, 8, 1093-1122.
73. de Groot, F. M. H.; van Berkom, L. W. A.; Scheeren, H. W. Synthesis and biological evaluation of 2′-carbamate-linked and 2′-carbonate-linked prodrugs of paclitaxel. Selective activation by the tumor-associated protease plasmin. J. Med. Chem. 2000, 43, 3093-3102.
74. de Groot, F. M. H.; Loos, W. J.; Koekkoek, R.; van Berkom, L. W. A.; Busscher, G. F.; Seelen, A. E.; Albrecht, C.; de Bruijn, P.; Scheeren, H. W. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release. J. Org. Chem. 2001, 66, 8815-8830.
75. Jaffar, M.; Williams, K. J.; Stratford, I J. Bioreductive and gene therapy approaches to hypoxic diseases. Adv. Drug Delivery Rev. 2001, 55, 217-228.
76. Brown, J. M.; Wilson, W. R. Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer 2004, 4, 437-447.
77. Seddon, B.; Kelland, L. R.; Workman, P. Bioreductive prodrugs for cancer therapy. Methods Mol. Med. 2004, 90, 515-542.
78. Denny, W. A. Hypoxia-activated anticancer drugs. Expert Opin. Ther. Pat. 2005, 15, 635-646.
79. Damen, E. W. P.; Nevalainen, T. J.; Van den Bergh, T. J. M.; De Groot, F. M. H.; Scheeren, H. W. Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue. Bioorg. Med. Chem. 2002, 10, 71-77.
80. Vrudhula, V. M.; MacMaster, J. F.; Li, Z.; Kerr, D. E.; Senter, P. D. Reductively activated disulfide prodrugs of paclitaxel. Bioorg. Med. Chem. Lett. 2002, 12, 3591-3594.
81. Volpert, O. V.; Ward, W. F.; Lingen, M. W.; Chesler, L.; Solt, D. B.; Johnson, M. D.; Molteni, A.; Polverini, P. J.; Bouck, N. P. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Invest. 1996, 98, 671-679.
82. Bagshawe, K. D.; Sharma, S. K.; Begent, R. H. J. Antibody-directed enzyme prodrua therapy (ADEPT) for cancer. Expert Opin. Biol. Ther. 2004, 4, 1777-1789.
83. Xu, G.; McLeod, H. L. Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res. 2001, 7, 3314-3324.
84. Rodrigues, M. L.; Carter, P.; Wirth, C.; Mullins, S.; Lee, A.; Blackburn, B. K. Synthesis and β-lactamase-mediated activation of a cephalosporin-Taxol prodrug. Chem. Biol. 1995, 2, 223-227.
85. Vrudhula, V. M.; Kerr, D. E.; Siemers, N. O.; Dubowchik, G. M.; Senter, P. D. Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-β-lactamase fusion protein. Bioorg. Med. Chem. Lett. 2003, 13, 539-542.
86. De Graaf, M.; Boven, E.; Scheeren, H. W.; Haisma, H. J.; Pinedo, H. M. Beta-glucuronidase-mediated drug release. Curr. Pharm. Des. 2002, 8, 1391-1403.
87. De Bont, D. B. A.; Leenders, R. G. G.; Haisma, H. J.; Van der Meulen-Muileman, L; Scheeren, H. W. Synthesis and biological activity of β-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT. Bioorg. Med. Chem. 1997, 5, 405-414.
88. Schmidt, F.; Ungureanu, I.; Duval, R.; Pompon, A.; Monneret, C. Cancer chemotherapy: A paclitaxel prodrug for ADEPT (antibody-directed enzyme prodrug therapy). Eur. J. Org. Chem. 2001, 11, 2129-2134.
89. Bouvier, E.; Thirot, S.; Schmidt, F.; Monneret, C. A new paclitaxel prodrug for use in ADEPT strategy. Org. Biomol. Chem. 2003, 1, 3343-3352.
90. El, Alaoui, A.; Saha, N.; Schmidt, F.; Monneret, C.; Florent, J. C. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy. Bioorg. Med. Chem. 2006, 14, 5012-5019.
91. Majumdar, S.; Duvvuri, S.; Mitra, A. K. Membrane transporter/receptor- targeted prodrug design: strategies for human and veterinary drug development. Adv. Drug Delivery Rev. 2004, 56, 1437-1452.
92. Safavy, A.; Raisch, K. P.; Khazaeli, M. B.; Buchsbaum, D. J.; Bonner, J. A. Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. J. Med. Chem. 1999, 42, 4919-4924.
93. Schally, A. V.; Nagy, A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur. J. Endocrinol. 1999, 141, 1-14.
94. Nagy, A.; Schally, A. V. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Curr. Pharm. Des. 2005, 11, 1167-1180.
95. Safavy, A.; Raisch, K. P.; Matusiak, D.; Bhatnagar, S.; Helson, L. Single-drug multiligand conjugates: synthesis and preliminary cytotoxicity evaluation of a paclitaxel-dipeptide "scorpion" molecule. Bioconjugate Chem. 2006, 17, 565-570.
96. Huang, C. M.; Wu, Y. T.; Chen, S. T. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem. Biol. 2000, 7, 453-461.
97. Chen, X.; Plasencia, C.; Hou, Y.; Neamati, N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J. Med. Chem. 2005, 48, 1098-1106.
98. Wang, S.; Low, P. S. Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. J. Controlled Release 1998, 53, 39-48.
99. Lu, Y.; Sega, E.; Leamon, C. P.; Low, P. S. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv. Drug Delivery Rev. 2004, 56, 1161-1176.
100. Lee, J. W.; Lu, J. Y.; Low, P. S.; Fuchs, P. L. Synthesis and evaluation of Taxol-folic acid conjugates as targeted antineoplastics. Bioorg. Med. Chem. 2002, 10, 2397-2414.
101. Liu, C.; Strobl, J. S.; Bane, S.; Schilling, J. K.; McCracken, M.; Chatterjee, S. K.; Rahim-Bata, R.; Kingston, D. G. I. Design, synthesis, and bioactivities of steroid-linked Taxol analogues as potential targeted drugs for prostate and breast cancer. J. Nat. Prod. 2004, 67, 152-159.
102. Skwarczynski, M.; Noguchi, M.; Hirota, S.; Sohma, Y.; Kimura, T.; Hayashi, Y.; Kiso, Y. Development of first photoresponsive prodrug of paclitaxel. Bioorg. Med. Chem. Lett. 2006, 16, 4492-4496.
103. Stevens, P. J.; Lee, R. J. A folate receptor-targeted emulsion formulation for paclitaxel. Anticancer Res. 2003, 23, 4927-4932.
104. Stevens, P. J.; Sekido, M.; Lee, R. J. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm. Res. 2004, 21, 2153-2157.
105. Zakharian, T. Y.; Seryshev, A.; Sitharaman, B.; Gilbert, B. E.; Knight, V.; Wilson, L. J. A fullerene-paclitaxel chemotherapeutic: synthesis, characterization, and study of biological activity in tissue culture. J. Am. Chem. Soc. 2005, 127, 12508-12509.
106. Ahmad, I.; Masters, G. R.; Schupsky, J. J.; Nguyen, J.; Ali. S.; Janoff, A. S.; Mayhew, E. Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice. Oncol. Res. 1999, 11, 273-280.
107. Ali, S.; Minchey, S.; Janoff, A.; Mayhew. E. A differential scanning calorimetry study of phosphocholines mixed with paclitaxel and its bromoacylated taxanes. Biophys. J. 2000, 78, 246-256.
108. Ali, S.; Ahmad, I.; Peters, A.; Masters, G.; Minchey, S.; Janoff, A.; Mayhew, E. Hydrolyzable hydrophobic taxanes: synthesis and anticancer activities. Anti-Cancer Drugs 2001, 12, 117-128.
109. Lundberg, B. B.; Risovic, V.; Ramaswamy, M.; Wasan, K. M. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J. Controlled Release 2003, 86, 93-100.
110. Rodrigues, D. G.; Maria, D. A.; Fernandes, D. C.; Valduga, C. J.; Couto, R. D.; Ibanez, O. C. M.; Maranhao, R. C. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother. Pharmacol. 2005, 55, 565-576.
111. Bradley, M. O.; Swindell, C. S.; Anthony, F. H.; Witman, P. A.; Devanesan, P.; Webb, N. L.; Baker, S. D.; Wolff, A. C.; Donehower, R. C. Tumor targeting by conjugation of DHA to paclitaxel. J. Controlled Release 2001, 74, 233-236.
112. Bradley, M. O.; Webb, N. L.; Anthony, F. H.; Devanesan, P.; Witman, P. A.; Hemamalini, S. Chander, M. C.; Baker, S. D; He, L.; Horwitz, S. B.; Swindell, C. S. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin. Cancer Res. 2001, 7, 3229-3238.
113. Sparreboom, A.; Wolff, A. C.; Verweij, J.; Zabelina, Y.; van Zomeren, D. M.; McIntire, G. L.; Swindell, C. S.; Donehower, R. C.; Baker. S. D. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: In vitro and clinical pharmacokinetic studies. Clin. Cancer Res. 2003, 9, 151-159.
114. Wolff, A. C.; Donehower, R. C.; Carducci, M. K.; Carducci, M. A.; Brahmer, J. R.; Zabelina, Y.; Bradley, M. O.; Anthony, F. H.; Swindell, C. S.; Witman, P. A.; Webb, N. L.; Baker, S. D. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin. Cancer Res. 2003, 9, 3589-3597.
115. Harries, M.; O'Donnell, A.; Scurr, M.; Reade, S.; Cole, C.; Judson, I.; Greystoke, A.; Twelves, C.; Kaye, S. Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. Br. J. Cancer 2004, 91, 1651-1655.
116. Nori, A.; Kopecek, J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug Delivery Rev. 2005, 57, 609-636.
117. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41, 189-207.
118. Maeda, H.; Sawa, T.; Konno, T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Controlled Release 2001, 74, 47-61.
119. Hoste, K.; De Winne, K.; Schacht, E. Polymeric prodrugs. Int. J. Pharm. 2004, 277, 119-131.
120. Greenwald, R. B.; Pendri, A.; Bolikal, D.; Gilbert, C. W. Highly water soluble taxol derivatives: 2′-polyethylene glycol esters as potential prodrugs. Bioorg. Med. Chem. Lett. 1994, 4, 2465-2470.
121. Greenwald, R. B.; Gilbert, C. W.; Pendri, A.; Conover, C. D.; Xia, J.; Martinez, A. Drug delivery systems: water soluble Taxol 2′-poly(ethylene glycol) ester prodrugs. Design and in vivo effectiveness. J. Med. Chem. 1996, 39, 424-431.
122. Pendri, A.; Conover, C. D.; Greenwald, R. B. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. Anti-Cancer Drug Des. 1998, 13, 387-395.
123. Li, C.; Yu, D.; Inoue, T.; Yang, D. J.; Milas, L.; Hunter, N. R.; Kim, E. E.; Wallace, S. Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug. Anti-Cancer Drugs 1996, 7, 642-648.
124. Ceruti, M.; Crosasso, P.; Brusa, P.; Arpicco, S.; Dosio, F.; Cattel, L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. J. Controlled Release 2000, 63, 141-153.
125. Feng, X.; Yuan, Y.-J.; Wu, J.-C. Synthesis and evaluation of water-soluble paclitaxel prodrugs. Bioorg. Med. Chem. Lett. 2002, 12, 3301-3303.
126. Rodrigues, P. C. A.; Scheuermann, K.; Stockmar, C.; Maier, G.; Fiebig, H. H.; Unger, C.; Muelhaupt, R.; Katz, F. Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates. Bioorg. Med. Chem. Lett. 2003, 13, 355-360.
127. Ulbrich, K.; Subr, V. Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Delivery Rev. 2004, 56, 123-1050.
128. Schoenmakers, R. G.; Van de'Wetering, P.; Elbert, D. L.; Hubbell, J. A. The effect of the linker on the hydrolysis rate of drug-linked ester bonds. J. Controlled Release 2004, 95, 291-300.
129. Zhang, X.; Li, Y.; Chen, X.; Wang, X.; Xu, X.; Liang, Q.; Hu, J.; Jing, X. Synthesis and characterization of the paclitaxel/MPEG-PLA block copolymer conjugate. Biomaterials 2005, 26, 2121-2128.
130. Choi, J.-S.; Jo, B. W. Enhanced paclitaxel bioavailability after oral administration of PEGylated paclitaxel prodrug for oral delivery in rats. Int. J. Pharm. 2004, 280, 221-227.
131. Choi, J. S.; Jo, B. W.; Kim, Y. C. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J. Pharm, Biopharm. 2004, 57, 313-318.
132. Choi, J. S.; Shin, S. C. Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. Int. J. Pharm. 2005, 292, 149-156.
133. Luo, Y.; Prestwich, G. D. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjugate Chem. 1999, 10, 755-763.
134. Luo, Y.; Ziebell, M. R.; Prestwich, G. D. A hyaluronic acid-Taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 2000, 1, 208-218.
135. Thierry, B.; Kujawa, P.; Tkaczyk, C.; Winnik, F. M.; Bilodeau, L.; Tabrizian, M. Delivery platform for hydrophobic drugs: prodrug approach combined with self-assembled multilayers. J. Am. Chem. Soc. 2005, 127, 1626-1627.
136. Rihova, B.; Kubackova, K. Clinical implications of N-(2-hydroxypropyl) methacrylamide copolymers. Curr. Pharm. Biotechnol 2003, 4, 311-322.
137. Duncan, R.; Gac-Breton, S.; Keane, R.; Musila, R.; Sat, Y. N.; Satchi, R.; Searle, F. Polymer-drug conjugates, polymer-directed enzyme prodrug therapy (PDEPT) and (polymer-enzyme liposome therapy) PELT: basic principles for design and transfer from the laboratory to clinic. J. Controlled Release 2001, 74, 135-146.
138. Meerum Terwogt, J. M.; ten Bokkel Huinink, W. W.; Schellens, J. H. M.; Schot, M.; Mandjes, I. A. M.; Zurlo, M. G.; Rocchetti, M.; Rosing, H.; Koopman, F. J.; Beijnen, J. H. Phase I clinical and pharmocokinetic study of PNU166945, a novel water soluble polymer-conjugated prodrug of paclitaxel. Anti-Cancer Drugs 2001. 12, 315-323.
139. Sugahara, S.; Kajiki, M.; Kuriyama, H.; Kobayashi, T. Paclitaxel delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboxymethyldextran to create prodrugs. Biol. Pharm. Bull. 2002, 25, 632-641.
140. Cavallaro, G.; Licciardi, M.; Caliceti, P.; Salmaso, S.; Giammona, G. Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug. Eur. J. Pharm. Biopharm. 2004. 58, 151-159.
141. Dhanikula, A. B.; Panchagnula, R. Preparation and characterization of water-soluble prodrug, liposomes and micelles of paclitaxel. Curr. Drug Delivery 2005, 2. 75-91.
142. Dhanikula, A. B.; Singh, D. R.; Panchagnula, R. In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of paclitaxel: Gel, film, prodrug, liposomes and micelles. Curr. Drug Delivery 2005, 2, 35-44.
143. Li, C. Poly(L-glutamic acid)-anticancer drug conjugates. Adv. Drug Delivery Rev. 2002, 54, 695-713.
144. Li, C.; Yu, D. F.; Newman, R. A.; Cabral, F.; Stephens, L. C.; Hunter, N.; Milas, L.; Wallace, S. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res. 1998, 58, 2404-2409.
145. Li, C.; Price, J. E.; Milas, L.; Hunter N. R.; Ke, S.; Yu, D. F.; Charnsangavej, C.; Wallace, S. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin. Cancer Res. 1999, 5, 891-897.
146. Oldham, E. A.; Li, C.; Ke, S.; Wallace, S.; Huang, P. Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells. Int. J. Oncol, 2000, 16, 125-132.
147. Li, C.; Newman, R. A.; Wu, Q.-P.; Ke, S.; Chen, W.; Hutto, T.; Kan, Z.; Bninnan, M. D.; Charnsangavej, C.; Wallace, S. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol. 2000, 46, 416-422.
148. Singer, J. W.; Baker, B.; De Vries, P.; Kumar, A.; Shaffer, S.; Vawter, E.; Bolton, M.; Garzone, P. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv. Exp. Med. Biol. 2003, 519, 81-99.
149. Auzenne, E.; Donato, N. J.; Li, C.; Leroux, E.; Price, R. E.; Farquhar, D.; Klostergaard, J. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with Taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin. Cancer Res. 2002, 8, 573-581.
150. Zou, Y.; Fu, H.; Ghosh, S.; Farquhar, D.; Klostergaard, J. Antitumor activity of hydrophilic paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin. Cancer Res. 2004, 10, 7382-7391.
151. Langer, C. J. Dilemmas in management: the controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax). Oncologist 2004, 9, 398-405.
152. Sabbatini, P.; Aghajanian, C.; Dizon, D.; Anderson, S.; Dupont, J.; Brown, J. V.; Peters, W. A.; Jacobs, A.; Mehdi, A.; Rivkin, S.; Eisenfeld, A. J.; Spriggs, D. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J. Clin. Oncol. 2004, 22, 4523-4531.
153. Veronese, M. L.; Flaherty, K.; Kramer A.; Konkle, B. A.; Morgan, M.; Stevenson, J. P.; O'Dwyer, P. J. Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2005, 55, 497-501.
154. Singer, J. W.; Shaffer, S.; Baker, B.; Bernareggi, A.; Stromatt, S.; Nienstedt, D.; Besman, M. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anti-Cancer Drugs 2005, 16, 243-254.
155. Boddy, A. V.; Plummer, E. R.; Todd, R.; Sludden, J.; Griffin, M.; Robson, L.; Cassidy, J.; Bissett, D.; Bernareggi, A.; Verrill, M. W.; Calvert, A. H. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin. Cancer Res. 2005, 11, 7834-7840.
156. Singer, J. W. Paclitaxel poliglumex (XYOTAX, CT-2103): A macromolecular taxane. J. Controlled Release 2005, 109, 120-126.
157. Li, C.; Ke, S.; Wu, Q. P.; Tansey, W.; Hunter, N.; Buchmiller, L. M.; Milas, L.; Charnsangavej, C.; Wallace, S. Potentiation of ovarian OCA-1 tumor radioresponse by poly(L,-glutamic acid)-paclitaxel conjugate. Int. J. Radiat. Oncol., Biol., Phys. 2000, 48, 1119-1126.
158. Li, C.; Ke, S.; Wu, Q. P.; Tansey, W.; Hunter, N.; Buchmiller, L. M.; Milas, L.; Charnsangavej, C.; Wallace, S. Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin. Cancer Res. 2000, 6, 2824-2834.
159. Milas, L.; Mason, K. A.; Hunter, N.; Li, C.; Wallace, S. Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability. Int. J. Radiat. Oncol., Biol. Phys. 2003, 55, 707-712.
160. Tishler, Roy B. Polymer-conjugated paclitaxel as a radiosensitizing agent. A big step forward for combined modality therapy. Int. J. Radiat. Oncol., Biol., Phys. 2003, 55, 563-564.
161. Kratz, F.; Beyer, U. Serum proteins as drug carriers of anticancer agents: a review. Drug Delivery 1998, 5, 281-299.
162. Tanaka, T.; Shiramoto, S.; Miyashita, M.; Fujishima, Y.; Kaneo, Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int. J. Pharm. 2004, 277, 39-61.
163. Bicamumpaka, C.; Page, M. In vitro cytotoxicity of paclitaxel-transferrin conjugate on H69 cells. Oncol. Rep. 1998, 5, 1381-1383.
164. Dosio, F.; Brusa, P.; Crosasso, P.; Arpicco, S.; Cattel, L. Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J. Controlled Release 1997, 47, 293-304.
165. Dosio, F.; Arpicco, S.; Brusa, P.; Stella, B.; Cattel, L. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics. J. Controlled Release 2001, 76, 107-117.
166. Boas, U.; Heegaard, P. M. H. Dendrimers in drug research. Chem. Soc. Rev. 2004, 33, 43-63.
167. De Groot, F. M. H.; Albrecht, C.; Koekkoek, R.; Beusker, P. H.; Scheeren, H. W. "Cascade-release dendrimers" liberate all end groups upon a single triggering event in the dendritic core. Angew. Chem., Int. Ed. 2003, 42, 4490-4494.
168. Keppler, D.; Sloane, B. F. Cathepsin B: multiple enzyme forms from a single gene and their relation to cancer. Enzyme Protein 1996, 49, 94-105.
169. Dubowchik, G. M.; Radia, S. Monomethoxytrityl (MMT) as a versatile amino protecting group for complex prodrugs of anticancer compounds sensitive to strong acids, bases and nucleophiles. Tetrahedron Lett. 1997, 38, 5257-5260.
170. Dubowchik, G. M.; Mesure, K.; Knipe, J. O.; Firestone, R. A. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg. Med. Chem. Lett. 1998, 8, 3347-3352.
171. Guillemard, V.; Saragovi, H. U. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res. 2001, 61, 694-699.
172. Saragovi, H. U.; Gehring, K. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol. Sci. 2000, 2, 93-98.
173. Safavy, A.; Bonner, J. A.; Waksal, H. W.; Buchsbaum, D. J.; Gillespie, G. Y.; Khazaeli, M. B.; Arani, R.; Chen, D. T.; Carpenter, M.; Raisch, K. P. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjugate Chem. 2003, 14, 302-310.
174. Saleh, M. N.; Raisch, K. P.; Stackhouse, M. A.; Grizzle, W. E.; Bonner, J. A.; Mayo, M. S.; Kim, H. G.; Meredith, R. F.; Wheeler, R. H.; Buchsbaum, D. J. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Blather. Radiopharm. 1999, 14, 451-463.
175. Safavy, A.; Georg, G. I.; Vander Velde, D.; Raisch, K. P.; Safavy, K.; Carpenter, M.; Wang, W.; Bonner, J. A.; Khazaeli, M. B.; Buchsbaum, D. J. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. Bioconjugate Chem. 2004, 15, 1264-1274.
176. Correa, J. J.; Page, M. Synthesis and evaluation of paclitaxel immunoconjugate with antitumor activity in vitro. Tumor Targeting Cancer Ther. 2002, 165-178.
177. Ojima, I.; Geng, X.; Wu, X.; Qu, C.; Borella, C. P.; Xie, H.; Wilhelm, S. D.; Leece, B. A.; Bartle, L. M.; Goldmacher, V. S.; Chari, R. V. J. Tumor-specific novel taxoid-monoclonal antibody conjugates. J. Med. Chem. 2002, 45, 5620-5623.
178. Allen, T. M.; Cullis, P. R. Drug delivery system: entering the main stream. Science 2004, 303, 1818-1822.